Ignite Creation Date:
2024-05-06 @ 11:12 AM
Last Modification Date:
2024-10-26 @ 12:41 PM
Study NCT ID:
NCT03450837
Status:
COMPLETED
Last Update Posted:
2018-03-01
First Post:
2018-02-15
Brief Title:
Impaired HDL and Coronary Artery Disease in Anabolic Androgenic Steroid Users
Sponsor:
University of Sao Paulo General Hospital
Organization:
University of Sao Paulo General Hospital
Study Overview
Official Title:
Diminished Macrophage Cholesterol Efflux Mediated by HDL and Coronary Artery Disease in Young Male Anabolic Androgenic Steroid Users
Status:
COMPLETED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Anabolic androgenic steroids AASs have been associated with coronary artery disease CAD The illicit use of these substances also leads to a remarkable decrease in high-density lipoprotein HDL plasma concentration which could be a key factor in the atherosclerotic process The investigators tested the functionality of HDL by cholesterol efflux and antioxidant capacity and its association with CAD in young men
Detailed Description:
Twenty strength-trained AAS users AASU age 295 yr 20 age-matched strength-trained AAS nonusers AASNU and 10 sedentary controls SC were enrolled
HDL concentration and functionality by measuring the 14C-cholesterol efflux mediated by HDL and the ability of HDL in inhibiting LDL oxidation were evaluated
Coronary artery was evaluated with coronary computed tomography angiography
HDL concentration and functionality by measuring the 14C-cholesterol efflux mediated by HDL and the ability of HDL in inhibiting LDL oxidation were evaluated
Coronary artery was evaluated with coronary computed tomography angiography
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None